Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus
about
The melanosomal/lysosomal protein OA1 has properties of a G protein-coupled receptorConstitutive internalization of the leucine-rich G protein-coupled receptor-5 (LGR5) to the trans-Golgi networkThe chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalizationStructural and functional impairment of endocytic pathways by retinitis pigmentosa mutant rhodopsin-arrestin complexesHeterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patternsPharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensorThe structural basis of arrestin-mediated regulation of G-protein-coupled receptorsA rapid and affordable screening platform for membrane protein trafficking.RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoformsLigand-specific endocytic dwell times control functional selectivity of the cannabinoid receptor 1A Single Amino Acid Mutation (R104P) in the E/DRY Motif of GPR40 Impairs Receptor FunctionAltered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.Beyond desensitization: physiological relevance of arrestin-dependent signaling.beta-Arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6.Quality control for unfolded proteins at the plasma membrane.G Protein and β-arrestin signaling bias at the ghrelin receptor.G-protein-coupled receptors for neurotransmitter amino acids: C-terminal tails, crowded signalosomes.Phenotypic regulation of the sphingosine 1-phosphate receptor miles apart by G protein-coupled receptor kinase 2.The stem cell-expressed receptor Lgr5 possesses canonical and functionally active molecular determinants critical to β-arrestin-2 recruitment.Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs).Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.Enhanced BRET Technology for the Monitoring of Agonist-Induced and Agonist-Independent Interactions between GPCRs and β-ArrestinsThe melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.Signaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus.Desensitization of herpesvirus-encoded G protein-coupled receptors.Function of non-visual arrestins in signaling and endocytosis of the gastrin-releasing peptide receptor (GRP receptor).Engineering visual arrestin-1 with special functional characteristicsFunctional polymorphisms affecting the clinically important arginine-137 residue of AVPR2 do not influence serum sodium concentration at the population levelTherapeutic potential of β-arrestin- and G protein-biased agonists.The β-Arrestins: Multifunctional Regulators of G Protein-coupled ReceptorsCommon structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors.Triphenylmethane dye activation of beta-arrestinMutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.Physiology and pathophysiology of the vasopressin-regulated renal water reabsorption.Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.Characterization of relaxin receptor (RXFP1) desensitization and internalization in primary human decidual cells and RXFP1-transfected HEK293 cellsParacrine transactivation of the CB1 cannabinoid receptor by AT1 angiotensin and other Gq/11 protein-coupled receptorsThe effect of aspartate-lysine-isoleucine and aspartate-arginine-tyrosine mutations on the expression and activity of vasopressin V2 receptor gene.
P2860
Q24306837-268AAB47-73C9-4D64-BDF7-4066B7EBBCCEQ24320381-F696683B-5DF0-472C-9564-2FEBD665AA2AQ24337078-8EEDAFFF-96D3-44AD-B1DD-EBFD640E3A3CQ24563320-39DBE195-954D-47B0-9193-1E67383654CEQ24618881-8B1BDCAF-ADA6-4D36-9BA3-4599C367DD36Q24627304-ED2716FB-2621-4AE6-92B9-CD0E17C55C64Q24657537-243AF47F-08AF-4914-9DC6-193DE96DA45AQ27305088-D9970EC0-8544-4047-8A4A-73A6718C9F70Q28182190-4F26BFB8-6866-409A-8EA9-B9F6F39E9BD9Q28245037-57A017AF-C973-49B1-A325-67E310919C4AQ28550523-14E179F7-D1A0-4337-B8EA-2B71FF76E4A9Q33632079-4C282873-5806-4A1B-AAEF-C02D8D1BA85BQ33862041-313F91B0-88EB-4189-8CAD-9FBFA8C61ACDQ33890802-A942C7D0-22DD-41D0-A19E-491B57F7A7AAQ34313590-E1441786-0A70-4539-917D-55DBA567C666Q34412404-1F3E75F8-57F8-4F5B-9DAE-CC08E46A1D7AQ34580340-5DEDA09F-F56C-4BEC-AE55-66D6C76870A6Q34634508-D4E5AB03-19DF-4091-9647-E57AE1231EA4Q35027128-DCAF2EEC-AC82-4E50-96C6-CB66BB80894AQ35080956-70A0A258-5DE7-4BAD-BFD7-C6C437CAECB6Q35223044-1CD58ABC-95F0-43AF-B18B-9AFCA090E74BQ35536256-0B2364B6-6433-4148-A2E9-1FF2DEA2D6E9Q35921791-1AB96E26-F5BA-441D-AAE5-B01408405AF8Q35971690-30887C3E-446C-4C8E-8646-7C056A5821DEQ36003378-2159B370-A6CF-4AB0-AF34-D8FAB797E32DQ36138589-1B6D87A6-7AD0-401B-8D87-FD80F1230BAFQ36454708-AC95E1C1-93EF-4F1D-8F7D-A6C60DEE844CQ36492513-2090B192-046B-4EE7-9F94-45BA149F98ABQ36579557-4C7598B3-A294-41AE-9F03-706D692BE969Q36737665-40AF1E98-E360-44A1-B10C-C33CBC887AB8Q36773331-539C37CF-C2FE-400B-9C20-1A200E571FE8Q36884777-559D2E53-F0A4-40EF-8EC0-105AEDC923ADQ36932581-7E5E380B-BC80-49A9-863C-7B1DDFC933BAQ37096786-69D92246-CD3C-48FF-ACCC-49F94522C741Q37137434-4DC3E827-9F01-4F7F-98B6-BBCD295781C4Q37145917-71994ED0-45D1-45B5-89A9-BCDA79F81322Q37155408-5F58C294-45F8-44E7-A4FC-1CF73ACF4A70Q37165951-B7C964F5-1061-4CD0-A0AB-FB5BD46A8463Q37285069-79752D91-2DF7-4538-820E-2923FADC9CD9Q37425609-BAA2EC96-B224-4029-9735-50CAE5571D40
P2860
Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
name
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@ast
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@en
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@nl
type
label
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@ast
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@en
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@nl
prefLabel
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@ast
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@en
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@nl
P2093
P2860
P356
P1476
Constitutive arrestin-mediated ...... nephrogenic diabetes insipidus
@en
P2093
R H Oakley
S A Laporte
P2860
P356
10.1073/PNAS.011303698
P407
P577
2001-01-01T00:00:00Z